Laura T. Safar, MD: Carefully Addressing Mental Health in MS
June 18th 2019The director of MS neuropsychiatry at Brigham and Women’s Hospital spoke of the importance of not oversimplifying the approach to mental health disorders in individuals with MS, and how the collaborative care model can help.­­­
Emily Splichal, DPM: Using Texture for Nerve Stimulation in the Feet
June 13th 2019Many patients with neurologic conditions such as multiple sclerosis are faced with gait and stability issues due to their disease, but Splichal and Naboso Technology seek to address these issues via mechanoreceptor stimulation.
Pitolisant Safety Data Shows Positive Signs for Those With Narcolepsy
June 12th 2019Investigators noted that, when considered with efficacy findings in narcolepsy, pitolisant has a favorable risk-benefit profile representative of advancement in the treatment of excessive daytime sleepiness and cataplexy in adult patients.
Mitchell Miglis, MD: A Bidirectional Link Between Autonomic Dysfunction, Hypersomnias
June 11th 2019The autonomic disorders and sleep medicine specialist at Stanford University spoke about the overlap of autonomic disorders in sleep medicine, an often underrepresented portion of the sleep medicine field.
Telemedicine Cognitive Behavioral Therapy for Insomnia Equals Face-to-Face Interactions
June 10th 2019The efficacy of CBT using the American Academy of Sleep Medicine (AASM) SleepTM platform has been shown to be similarly efficacious to face-to-face physician encounters in 30 adults with chronic insomnia.
Noah Rosen, MD: Lessons Learned From the Father of Neurology
June 5th 2019The program director of neurology at Zucker School of Medicine, Northwell Health, reviewed the contributions of neurologist S. Weir Mitchell, MD, and how today’s neurologists can gain insights for their own practice from Mitchell’s complicated history.
MS Patients With Positive Prognostic Profiles Less Likely to Initiate Recommended DMTs
May 31st 2019Patients with favorable prognostic profiles or relapsing-remitting MS are the least likely to initiate high-efficacy disease-modifying therapies recommended by their physician, with many patients citing access challenges.
Carrie Hersh, DO, MSc: Shared Decision Making in Multiple Sclerosis
May 31st 2019The MS neurologist at Cleveland Clinic’s Lou Ruvo Center for Brain Health spoke about the factors that should be taken into account when making treatment decisions in MS, such as tolerability, affordability, and the desire to start family planning.
Alemtuzumab Maintains Long-Term Efficacy in MS, Shows Superiority to Interferon Beta
May 30th 2019Follow-up data extending out to 8 years suggest that both clinical and MRI outcomes are better with alemtuzumab (Lemtrada) than interferon beta-1a in patients with relapsing-remitting multiple sclerosis.
Higher-Efficacy DMTs May Have Favorable Effect on Depression in MS
May 29th 2019Given that depression is a common symptom in patients with MS and is associated with increased morbidity and mortality, the investigators examined the effects of lower-efficacy DMTs and higher-efficacy DMTs on depression.